Free idea by Ingrid L. M. Souza
Hello everyone,
I would like to share freely my idea for the production of a vaccine. I would produce the vaccine with the peptide PRRARS|V present in the spike 2 (S2) glycoprotein of the viral SARS-CoV-2 envelope. This sequence is a cleavage site for a human enzyme called furin (which is abundant in respiratory tract). When the cleavage of Spike2 (S2) by the furin occurs it becomes in the right conformation and active to bind to ACE2 (angiotensin receptor 2), which is present in human cell plasma membrane. When they bind (S2-ACE2) the virus is able to make its entry in the cell. If this cleavage sequence site PRRARS|V of viral S2 be blocked by an especific antibody, the cleavage does not occur and S2 does not bind to receptor ACE2, consequently the virus entry does not occur either. Besides, an specific antibody against this cleavage site of S2 can produce an directional immune response allowing macrophages to recognize antibodies, to do phagocytosis and then destruct the virus.
Also, if you do a blast and alignment of the peptide sequence PRRARS|V you see that it has similarity only with bacterias, parasites, fungi and virus, only pathogens and THIS SEQUENCE IS NOT PRESENT IN HUMAN PROTEINS, which means that antibodies against it would NOT injure our cells or damage cell’s metabolism. I already worked with furins and I don’t recommend treating patients with furin inhibitor drugs once furin are necessary to cleave other proteins in the cell to maintain an healthy metabolism! The ideia is attack specific peptides of the virus, create specific response and avoid damaging our cells proteins and metabolism! Please share freely this ideia to laboratories around the world engaged to create a vaccine with this peptide whether recombinant or not against SARS-CoV-2. You can check some information at: https://www.virology.ws/2020/02/13/furin-cleavage-site-in-the-sars-cov-2-coronavirus-glycoprotein/ You can check the BLAST sequence PRRARS|V similarities with other species but not humans in the following photos...
Full text attached. SHARE IT.
You can check the following articles:
https://www.researchgate.net/publication/339746269_The_outbreak_of_SARS-CoV-2_pneumonia_calls_for_viral_vaccines
Great, Nandi,
The whole world need you very urgently, You will be famous like Pele in Soccer from Brazil
A potential problem with some vaccines is the over reaction of the immune system, at least for macaques there was large mortality in subsequent infection with SARS-1 after vaccination with S-IgG.
https://insight.jci.org/articles/view/123158
About the idea proposed , is this peptide sequence exposed in the closed conformation of the spike protein? The spike protein of SARS-2 has three S1 units that are closed and behind these are the S2 units, when an ACE2 receptor is near the virus , one leg of the S1 unit changes conformation, then the furin cleaves inside the spike protein and the viral RNA passes in the cell, the closed conformation is a way to avoid antibody response, if the proposed antibody for the S2 sequence can't bind because the virus has this antibody sequence in an enclosed space then the antibody response to SARS-2 may be low.
Regarding the strong immune reactions - maybe specific small molecule antagonists that block the cleavage would be safer than antibodies?
Article Small Molecules Blocking the Entry of Severe Acute Respirato...
Hard realities of COVID-19: A vaccine unlikely because the virus (SARS-CoV-2) causes a short-lived immunity.
Please read the following article for the shocking implications that world has to live with COVID-19 by preventive measures.
https://www.medrxiv.org/content/10.1101/2020.06.13.20130252v1.full.pdf
These are the breaking articles describing initial results of the COVID-19 vaccines from UK and China respectively.
1. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931604-4
2. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial
https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931605-6